When added to standard treatment, the rindopepimut vaccine could be beneficial for a subset of patients with recurrent glioblastoma, according to preliminary data from the ReACT trial.
Promising results from the Phase II trial originally were presented at the 2015 annual meeting of the American Society of Clinical Oncology, and now mature data provide clear evidence that the immunotherapy significantly improves a number of end points in addition to survival in patients with the epidermal